|
Eosinophilic esophagitis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Eosinophilic esophagitis (EoE) is a chronic, esophageal, type 2 inflammatory response associated with increased serum levels of interleukin 13 (IL13), which might contribute to its pathogenesis.
|
30395812 |
2019 |
|
Eosinophilic esophagitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The overlap between the IL-13-stimulated epithelial cell transcriptome and the respective disease transcriptome was 22, 9, and 5% in EoE, AD, and AA, respectively, indicating a greater involvement of the IL-13 pathway in EoE than AA (<i>p</i> = 0.0007) or AD (<i>p</i> = 0.02).
|
31824894 |
2019 |
|
Eosinophilic esophagitis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here, we aimed to determine the IL-13-mediated barrier dysfunction and expression of TJ-related proteins in EoE and to characterize interactions among TJ-related proteins involved in the barrier function of the esophageal epithelium.
|
29746170 |
2018 |
|
Eosinophilic esophagitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
IL-13 antagonists can be a promising therapy for EoE and dilation is a safe and effective treatment modality in patients with EoE but as is expected, does not decrease inflammation.
|
30015687 |
2018 |
|
Eosinophilic esophagitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The mechanism by which food allergens trigger EoE is thought to be a T helper type 2 (Th2) reaction, resulting in secretion of the cytokines IL-4, IL-5, and IL-13.
|
29372536 |
2018 |
|
Eosinophilic esophagitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Herein, we have reviewed the current evidence regarding efficacy and safety of monoclonal antibodies including mepolizumab (anti-IL-5), reslizumab (anti-IL-5), QAX576 (anti-IL-13), omalizumab (anti-immunoglobulin-E), and infliximab (anti-TNF-α) in treatment of EoE.
|
29234969 |
2018 |
|
Eosinophilic esophagitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Studies using biologics that target IL-13 pathways in the treatment of eosinophilic esophagitis have demonstrated substantial promise.
|
29859203 |
2018 |
|
Eosinophilic esophagitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
This review summarizes the established knowledge that has accumulated regarding the roles of IL-4, IL-13, and their receptors in allergic diseases, with an emphasis on asthma, atopic dermatitis and eosinophilic esophagitis.
|
29736903 |
2018 |
|
Eosinophilic esophagitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Additional control of Th2 inflammation can be achieved in select asthma patients with biologic therapies such as anti-IL-5 and anti-IL-13 antibodies, which have also been trialed in EoE.
|
28831387 |
2017 |
|
Eosinophilic esophagitis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The CAPN14 gene is positioned in an epigenetic hotspot regulated by IL-13, a T<sub>H</sub>2 cytokine with increased levels in patients with EoE that has been shown to be a mediator of the disease.
|
28131390 |
2017 |
|
Eosinophilic esophagitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition to providing a definitive EoE diagnosis with high accuracy, the EDP has been useful in elucidating several key elements about the disease including the efficacy of specific drugs such as swallowed glucocorticoids and anti-IL-13 humanized antibody therapy, the relationship between EoE and PPI-responsive esophageal eosinophilia, and predicting the disease course and responsiveness to therapy.
|
28770203 |
2017 |
|
Eosinophilic esophagitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, we demonstrate that SYNPO is induced by IL-13 in vitro and in vivo, is a nonredundant regulator of epithelial cell barrier function and motility, and is likely involved in EoE pathogenesis.
|
29046486 |
2017 |
|
Eosinophilic esophagitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results support further investigation of RPC4046 for IL-13-related allergic/inflammatory diseases (e.g., asthma and eosinophilic esophagitis).
|
28455782 |
2017 |
|
Eosinophilic esophagitis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Eotaxin-3, IL-5 and IL-13 were overexpressed in EoE.
|
28428721 |
2017 |
|
Eosinophilic esophagitis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Esophageal LRRC31 mRNA and protein increased in active EoE and strongly correlated with esophageal eosinophilia and IL13 and CCL26 (chemokine (C-C motif) ligand 26) mRNA expression.
|
26462420 |
2016 |
|
Eosinophilic esophagitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We conclude that IL-33 gene expression is associated with pediatric EoE development and that application of recombinant protein in mice phenocopies the early clinical phase of the human disease in an IL-13-dependent manner.
|
26514775 |
2016 |
|
Eosinophilic esophagitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We evaluated QAX576, an mAb against IL-13, in the treatment of patients with EoE.
|
25226850 |
2015 |
|
Eosinophilic esophagitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Epithelial barrier protein desmoglein 1, bone morphogenetic protein antagonist follistatin, neurotrophic tyrosine kinase receptor type 1, and CAPN14 have been defined as new potential therapeutic targets in EoE as regulators of the inflammatory interleukin-13-axis.
|
26418324 |
2015 |
|
Eosinophilic esophagitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Genetic studies have shown that EoE is associated with single nucleotide polymorphism on genes, which are released by the epithelium and important in atopic inflammation such as thymic stromal lymphopoietin located (TSLP) close to the Th2 cytokine cluster [interleukin (IL)-4, IL-5, IL-13] on chromosome 5q22, Calpain 14, EMSY, and Eotaxin3.
|
26258919 |
2015 |
|
Eosinophilic esophagitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Notably, 286 genes that were modified by IL-13 in the ALI system overlapped with the gene signature present within the inflamed esophageal tissue from patients with eosinophilic esophagitis (EoE), an allergic inflammatory disorder of the esophagus that is characterized by elevated IL-13 levels, altered epithelial differentiation, and pro-inflammatory gene expression.
|
26039063 |
2015 |
|
Eosinophilic esophagitis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
An EoE-specific-transcript signature is typically composed of IL-13-inducible and eosinophil-related genes, including eotaxin-3/C-C chemokine ligand 26 (CCL26).
|
26117258 |
2015 |
|
Eosinophilic esophagitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, these data identify a functional role for DSG1 and its dysregulation by IL-13 in the pathophysiology of EoE and suggest that the loss of DSG1 may potentiate allergic inflammation through the induction of pro-inflammatory mediators such as POSTN.
|
24220297 |
2014 |
|
Eosinophilic esophagitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together, these data comprise new potential biomarkers of EoE and demonstrate a novel role for lncRNAs in EoE and IL-13-associated responses.
|
24920534 |
2014 |
|
Eosinophilic esophagitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In consecutive adult patients with an EoE phenotype (dysphagia/food impaction, typical endoscopic findings and > 15 eos/HPF), gene expression of eotaxin-3, IL-13, and IL-5 were determined in distal and proximal oesophagus, at baseline and after omeprazole 40 mg b.d. for 8 weeks.
|
25112708 |
2014 |
|
Eosinophilic esophagitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Similarly, we found that esophageal eosinophilia in IL-4/IL-13 double gene-deficient and STAT6 gene-deficient mice were also not reduced following allergen-induced experimental EoE.
|
23689305 |
2013 |